Nearly 60,000 Americans will be diagnosed with pancreatic cancer this year, according to the American Cancer Society. That’s a grim statistic on its own. But a growing body of epidemiological evidence now points to an unlikely contributor: aspartame, the world’s most widely used artificial sweetener, could be increasing the risk of one of its deadliest forms — pancreatic ductal adenocarcinoma (PDAC).
And while climate change-driven heat waves dominate headlines, a quieter threat may be lurking in diet sodas and sugar-free snacks. A new study from the French National Institute for Health and Medical Research (INSERM), published in PLoS Medicine, adds weight to earlier evidence linking aspartame to several cancers, but this time the focus is sharpened on PDAC — a cancer with a five-year survival rate of just 12%.
Let’s be clear: pancreatic cancer is multifactorial. Smoking, obesity, family history — these are the heavy hitters. But the aspartame link, if causal, could shift public health messaging around artificial sweeteners in ways regulators have so far resisted.
The Evidence Linking Aspartame to Pancreatic Cancer
The INSERM team analyzed data from the NutriNet-Santé cohort, a massive French study launched in 2009 that follows more than 100,000 adults. Participants report everything they eat and drink, including brands and sweetener types. The researchers cross-referenced those records against cancer registries, and after a median follow-up of 7.7 years, they found something unsettling.
People who consumed aspartame at the highest levels — roughly the equivalent of one to two diet sodas per day — showed a statistically significant increase in pancreatic cancer risk compared to non-users. Specifically, for every additional 10 milligrams of aspartame consumed daily (about a quarter of a can of diet soda), the risk of PDAC rose by 15% after adjusting for age, sex, smoking, and other confounders.
That’s an effect size that demands attention. Dr. Mathilde Touvier, the study’s senior author and a research director at INSERM, told QuasarPost, “The association we observed was consistent across multiple sensitivity analyses. While we cannot claim causation from an observational study, the dose-response relationship is striking.”
It’s not the first study to flag aspartame. The IARC (International Agency for Research on Cancer) classified aspartame as “possibly carcinogenic to humans” (Group 2B) in July 2023, based largely on the same French data. But that classification stopped short of implicating specific organs. The new analysis drills into the pancreas — and the subtype matters. PDAC accounts for over 90% of all pancreatic cancers, and it’s notoriously difficult to treat because it’s usually caught late.
What the Latest Study Found — and What It Doesn’t
The INSERM study followed participants for nearly a decade. But pancreatic cancer has a long latency; some experts argue that follow-up periods need to be 15–20 years to truly capture diet-related risks. Dr. Michael F. Jacobson, co-founder of the Center for Science in the Public Interest, acknowledged this limitation in an interview. “Observational studies like this can’t prove causation, but when you see a consistent signal across multiple populations — as we do with aspartame and pancreatic cancer — it’s foolish to ignore it.”
He’s referring to earlier work from the NIH-AARP Diet and Health Study, which in 2006 found that men who drank more than one diet soda per day had a higher risk of non-Hodgkin lymphoma and multiple myeloma. But the pancreatic link was muddier there. The INSERM study is the largest to date to specifically examine artificial sweeteners and PDAC with detailed dietary records — not just food-frequency questionnaires.
One crucial nuance: the study also looked at other artificial sweeteners like acesulfame-K and sucralose. Neither showed a statistically significant association with PDAC, though both are under scrutiny for other cancers. This suggests that if there’s a mechanistic pathway, it may be specific to aspartame’s breakdown products: aspartic acid, phenylalanine, and methanol.
“Aspartame is metabolized in the gut to methanol, which is then converted to formaldehyde — a known carcinogen. That’s the biological plausibility,” says Dr. Robert Turesky, a toxicologist at the University of Minnesota who studies dietary carcinogens. “The question is whether the concentrations reaching the pancreas are high enough to initiate tumorigenesis. We don’t have that answer yet.”
How Does Aspartame Affect the Pancreas?
The pancreas is a metabolic workhorse. It produces insulin and digestive enzymes. Constant exposure to dietary toxins or metabolites can stress its cells, especially the ductal cells that line the pancreatic ducts — precisely where PDAC originates. Animal studies have shown that aspartame exposure in rats leads to increased pancreatic weight and histopathological changes, though translating those doses to human intake is tricky.
The INSERM study didn’t measure methanol or formaldehyde levels in participants. That’s the next logical step. But as Dr. Touvier points out, biomarkers are expensive and invasive to collect in large cohorts. For now, the epidemiological signal is the best we have.
It’s also worth noting that the FDA has set the acceptable daily intake (ADI) for aspartame at 50 mg per kilogram of body weight — far above what most people consume. But ADIs are based on old toxicity studies that didn’t focus on cancer endpoints, particularly pancreatic cancer. Critics argue that the ADI needs re-evaluation.
What This Means for Consumers
So, should you ditch your Diet Coke? The answer isn’t simple. For most healthy adults, occasional consumption probably poses negligible risk. But for heavy users — say, people who drink three or four diet sodas daily — the cumulative exposure over years or decades may be meaningful.
Dr. Jacobson advises caution: “If you’re using diet sodas for weight control, the evidence that they actually help is weak, and the potential cancer risk is growing. Water, tea, or unsweetened coffee are better options.”
Regulators may be forced to act if additional studies confirm the PDAC link. The European Food Safety Authority (EFSA) re-evaluated aspartame in 2013 and deemed it safe, but noted that new evidence could trigger a reassessment. That was before the IARC classification and the latest INSERM data. Public health advocacy groups are already calling for updated warnings.
What’s next? Researchers are planning a pooled analysis of multiple cohort studies to increase statistical power. They’re also exploring whether genetic variants in metabolism pathways — such as alcohol dehydrogenase or catalase — modify the risk. Until those answers come, the precautionary principle suggests that less aspartame is better, especially for those already at higher pancreatic cancer risk due to smoking, diabetes, or family history.
Look — science moves slowly while your pancreas works daily. The link isn’t proven, but it’s plausible, and the stakes couldn’t be higher.
Frequently Asked Questions
Is aspartame definitely linked to pancreatic ductal adenocarcinoma?
No. The new study from INSERM shows a statistical association, not proven causation. More research is needed, but the evidence is strong enough that the IARC classifies aspartame as “possibly carcinogenic to humans.”
How much aspartame is considered risky?
In the NutriNet-Santé study, the highest consumption group (about 40 mg/day, equivalent to 1–2 diet sodas) showed a 15% increased risk per 10 mg increment. But individual risk depends on many factors. The FDA’s ADI is 50 mg/kg/day, far above that, but the ADI isn’t specific to cancer.
Should I stop using artificial sweeteners?
It depends on your overall health profile. If you are at elevated risk for pancreatic cancer (smoking, obesity, diabetes, family history), reducing intake is a prudent step. For occasional use, the risk is likely low. Unsweetened beverages are the safest bet.
